Dr. McKay on FDA Approval of Frontline Cabozantinib in RCC

Name: Dr. McKay on FDA Approval of Frontline Cabozantinib in RCC
Uploaded: 2017-12-20T02:13:00.000Z
Description: Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).

December 19, 2017

Rana R. McKay, MD

Video

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).